| 000 | 01778 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516151251.0 | ||
| 264 | 0 | _c20131209 | |
| 008 | 201312s 0 0 eng d | ||
| 022 | _a1932-6203 | ||
| 024 | 7 |
_a10.1371/journal.pone.0063338 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBuqué, Aitziber | |
| 245 | 0 | 0 |
_aThymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells. _h[electronic resource] |
| 260 |
_bPloS one _c2013 |
||
| 300 |
_ae63338 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aCisplatin _xpharmacology |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aFolic Acid Antagonists _xpharmacology |
| 650 | 0 | 4 | _aGene Expression Profiling |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 |
_aGlutamates _xpharmacology |
| 650 | 0 | 4 |
_aGuanine _xanalogs & derivatives |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aOrgan Specificity |
| 650 | 0 | 4 | _aPemetrexed |
| 650 | 0 | 4 |
_aPurines _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyrimidines _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aThymidylate Synthase _xantagonists & inhibitors |
| 700 | 1 | _aAresti, Unai | |
| 700 | 1 | _aCalvo, Begoña | |
| 700 | 1 | _aSh Muhialdin, Jangi | |
| 700 | 1 | _aMuñoz, Alberto | |
| 700 | 1 | _aCarrera, Sergio | |
| 700 | 1 | _aAzkona, Eider | |
| 700 | 1 | _aRubio, Itziar | |
| 700 | 1 | _aLópez-Vivanco, Guillermo | |
| 773 | 0 |
_tPloS one _gvol. 8 _gno. 5 _gp. e63338 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1371/journal.pone.0063338 _zAvailable from publisher's website |
| 999 |
_c22752661 _d22752661 |
||